Animal models of non-alcoholic steatohepatitis: Of mice and man

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 247-254

  Schattenberg, J M ^a   Galle, P R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Animal models; Cell death; Cytokines; Insulin resistance; Metabolic syndrome; Non alcoholic steatohepatitis

Indexed keywords

AGOUTI PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

DISEASE COURSE; DISEASE MODEL; ENERGY EXPENDITURE; EXPERIMENTAL MOUSE; FATTY ACID OXIDATION; FEEDING BEHAVIOR; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENOME; LIFESTYLE; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHOLINE DEFICIENCY; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; LIVER; METHIONINE; MICE;

EID: 77952562217     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282097     Document Type: Review

References (71)

1. Brown WV, Fujioka K, Wilson PW, Wood-worth KA: Obesity: why be concerned? Am J Med 2009;122(suppl 1):S4-S11.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
3. Brunt EM: Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009;13: 533-54 4.
4. Page JM, Harrison SA: NASH and HCC. Clin Liver Dis 2009;13:631-647.
5. Donadon V, Balbi M, Perciaccante A, Casarin P, Zanette G: Insulin resistance and hyperinsulinemia in patients with chronic liver disease and hepatocellular carcinoma. Clin Med Endocrinol Diabetes 2009;2:25-33.
6. Siegel AB, Zhu AX: Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;15:5651-5661.
7. Schattenberg JM: Insulin resistance - a link between inflammation and hepatocarcinogenesis? Clin Med Endocrinol Diabetes 2009;2:1-4.
8. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967.
9. Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
10. Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-678.
11. Larter CZ, Yeh MM: Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23:1635-1648.
12. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM: Mechanisms of hepatic steatosis in mice fed a lipogenic methi-onine choline-deficient diet. J Lipid Res 2008;49:1068-1076.
13. Schattenberg JM, Singh R, Wang Y, et al: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006;43:163-172.
14. Chowdhry S, Nazmy MH, Meakin PJ, et al: Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010;48:357-371.
15. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
16. Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC: MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 2008;49:407-416.
17. Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ: N-acetyl-cysteine attenuates progression of liver pathology in a rat model of nonalcoholic steato-hepatitis. J Nutr 2008;138:1872-1879.
18. Oz HS, Im HJ, Chen TS, de Villiers WJ, Mc-Clain CJ: Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol 2006;20:39-47.
19. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM: Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G1070-G1077.
20. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J: Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med 2009;24:171-180.
21. George J, Pera N, Phung N, Leclercq I, Yun HJ, Farrell G: Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003;39:756-764.
22. Rinella ME, Green RM: The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47-51.
23. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ: Hepatocyte CYP2E1 overex-pression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005;280:9887-9894.
24. Yamaguchi K, Yang L, McCall S, et al: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-1374.
25. Nakae D, Yoshiji H, Mizumoto Y, et al: High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992;52:5042-5045.
26. Fujita K, Nozaki Y, Yoneda M, et al: Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, L-amino acid-defined diet-fed rat model. Alcohol Clin Exp Res 2008;34:S18-S24.
27. de Lima VM, Oliveira CP, Alves VA, et al: A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol 2008;49:1055-1061.
28. Kitade M, Yoshiji H, Kojima H, et al: Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steato-hepatitis in rats. Hepatology 2006;44:983-991.
29. Omagari K, Kato S, Tsuneyama K, et al: Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. Dig Dis Sci 2008;53:3206-3212.
30. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martinez-Chantar ML: Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 2009;41:969-976.
31. Deng QG, She H, Cheng JH, et al: Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005;42:905-914.
32. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
33. de Oliveira CP, de Lima VM, Simplicio FI, et al: Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment. J Am Coll Nutr 2008;27:299-305.
34. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA: Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295:G987-G995.
35. DeCarli LM, Lieber CS: Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet. J Nutr 1967;91:331-336.
36. Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ: A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 2008;294:G27-G38.
37. Zou Y, Li J, Lu C, et al: High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006;79:1100-1107.
38. Ito M, Suzuki J, Sasaki M, et al: Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol Res 2006;34:92-98.
39. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P: Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985;57:65-73.
40. Jeong WI, Jeong DH, Do SH, et al: Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 2005;67:235-242.
41. Matsuzawa N, Takamura T, Kurita S, et al: Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007;46:1392-1403.
42. Ando H, Takamura T, Matsuzawa-Nagata N, et al: The hepatic circadian clock is preserved in a lipid-induced mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2009;380:684-688.
43. Kirsch R, Clarkson V, Shephard EG, et al: Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 2003;18:1272-1282.
44. Yamazaki Y, Kakizaki S, Takizawa D, et al: Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2008;23:276-282.
45. Merriman RB, Aouizerat BE, Bass NM: Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(suppl 1):S30-S33.
46. Ayala I, Castillo AM, Adanez G, Fernandez-Rufete A, Perez BG, Castells MT: Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. Exp Biol Med (Maywood) 2009;234:10-16.
47. Friedman JM: Obesity: Causes and control of excess body fat. Nature 2009;459:340-342.
48. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
49. Ha laas J L, Boozer C, Blair-West J, Fida husein N, Denton DA, Friedman JM: Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997;94:8878-8883.
50. Halaas JL, Gajiwala KS, Maffei M, et al: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
51. Chen H, Charlat O, Tartaglia LA, et al: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-495.
52. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-2562.
53. Li Z, Yang S, Lin H, et al: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 20 03;37: 343-350.
54. Leclercq IA, Farrell GC, Schriemer R, Robertson GR: Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-213.
55. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM: Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000;31:633-640.
56. Sahai A, Malladi P, Pan X, et al: Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:G1035- G1043.
57. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H: Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998;101:2331-2339.
58. Nakayama H, Otabe S, Ueno T, et al: Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 2007;56:470-475.
59. Masaki T, Chiba S, Tatsukawa H, et al: Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004;40:177-184.
60. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al: A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006;169:846-860.
61. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999;103:1489-1498.
62. Koteish A, Diehl AM: Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
63. Muoio DM, MacLean PS, Lang DB, et al: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002;277:26089-26097.
64. Gavrilova O, Haluzik M, Matsusue K, et al: Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-34276.
65. Yanagitani A, Yamada S, Yasui S, et al: Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004;40:366-375.
66. Shiota G: Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor: A NASH animal model. Hepatol Res 2005;33:155-160.
67. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK: Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273:15639-15645.
68. Sun B, Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008;27:6228-6244.
69. Luedde T, Beraza N, Kotsikoris V, et al: Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepa-tocellular carcinoma. Cancer Cell 2007;11:119-132.
70. Beraza N, Malato Y, Vander BS, et al: Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 2008;57:655-663.
71. Watanabe S, Horie Y, Kataoka E, et al: Nonalcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 2007;22(suppl 1):S96-S100.